These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19256502)

  • 1. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
    Cashman JR; Voelker T; Zhang HT; O'Donnell JM
    J Med Chem; 2009 Mar; 52(6):1530-9. PubMed ID: 19256502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
    Cashman JR; Voelker T; Johnson R; Janowsky A
    Bioorg Med Chem; 2009 Jan; 17(1):337-43. PubMed ID: 19014888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.
    Cashman JR; Ghirmai S
    Bioorg Med Chem; 2009 Oct; 17(19):6890-7. PubMed ID: 19740668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
    Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
    Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice.
    Vijaya Kumar K; Rudra A; Sreedhara MV; Siva Subramani T; Prasad DS; Das ML; Murugesan S; Yadav R; Trivedi RK; Louis JV; Li YW; Bristow LJ; Naidu PS; Vikramadithyan RK
    Brain Behav Immun; 2014 Nov; 42():204-11. PubMed ID: 25016199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of action of antidepressants: new data from Escitalopram].
    Fabre V; Hamon M
    Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
    Bianchi M; Moser C; Lazzarini C; Vecchiato E; Crespi F
    Exp Brain Res; 2002 Mar; 143(2):191-7. PubMed ID: 11880895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
    Jones CK; Eastwood BJ; Need AB; Shannon HE
    Neuropharmacology; 2006 Dec; 51(7-8):1172-80. PubMed ID: 17045620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile.
    Dorsey JM; Miranda MG; Cozzi NV; Pinney KG
    Bioorg Med Chem; 2004 Mar; 12(6):1483-91. PubMed ID: 15018922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats.
    Cervantes-Durán C; Rocha-González HI; Granados-Soto V
    Neuroscience; 2013 Nov; 252():396-409. PubMed ID: 23994595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
    Taguchi R; Shikata K; Furuya Y; Ino M; Shin K; Shibata H
    Behav Brain Res; 2016 Oct; 312():138-47. PubMed ID: 27297028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
    Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor.
    Qin JJ; Chen HX; Zhao N; Yuan L; Zhang YZ; Yang RF; Zhang LM; Li YF
    Neurosci Lett; 2014 Oct; 582():104-8. PubMed ID: 25220701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effect of 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol, a putative trace amine receptor ligand involves l-arginine-nitric oxide-cyclic guanosine monophosphate pathway.
    Dhir A; Kulkarni SK
    Neurosci Lett; 2011 Oct; 503(2):120-4. PubMed ID: 21875647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
    Herold F; Chodkowski A; Izbicki Ł; Turło J; Dawidowski M; Kleps J; Nowak G; Stachowicz K; Dybała M; Siwek A; Mazurek AP; Mazurek A; Pluciński F
    Eur J Med Chem; 2011 Jan; 46(1):142-9. PubMed ID: 21093118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.
    Wen H; Qin W; Yang G; Guo Y
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression.
    Kanekar S; Ettaro R; Hoffman MD; Ombach HJ; Brown J; Lynch C; Sheth CS; Renshaw PF
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart.
    Lourenco CM; Kenk M; Beanlands RS; DaSilva JN
    Life Sci; 2006 Jun; 79(4):356-64. PubMed ID: 16499932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.